3Cawello W,Leonhardt A,Schweer H,etal.Dose proportional pharmacokinetics of alpro-stadil （prostaglandin E1）in healthyvolunteers following intravenous infusion 〔J〕.Br J Clin Pharmacol,1995,40：273～276.
4Anggard E.The biological activities of three metabolites of prostaglandin E1 〔J〕.ActaPhysiol Scand,1996,66：509～510.
5Yasuda H,Maeda K,Sonobe M,et al.Metabolic effect of PGE1 analogue O1206.αCD onnerve Na＋-K＋-ATPase activity of rats with streptozotocin-induced diabetes is mediatedvia cAMP: possible role of cAMP in diabetic neuropathy 〔J〕.Prostaglandins,1994,47：367～378.
6Okada S,Ichiki K,Tanokuchi S,et al.Effect of prostaglandin E1 on therenin-aldosterone system in patients with diabetic nephropathy 〔J〕.J Int MedRes,1993,21：126～132.
7Young MJ, Veves A,Smith JV, et al.Restoring lower limb blood flow improvesconduction velocity in diabetic patients 〔J〕.Diabetologia,1995,38：1051～1054.
8Partanen J,Niskanen L,Lehtinen J,et al.Natural history of peripheral neuropathy inpatients with non-insulin-dependent diabetes mellitus 〔J〕. N Engl J Med,1995,333：89～94.
9Yasuda H,Sonobe M,Hatanaka I,et al.A new prostaglandin E1 analogue （TFC-612）prevents a decrease in motor conduction velocity in streptozocin-diabetic rats 〔J〕.BiochemBiophys Res Commun,1998,150：225～230.
10Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1.αCD on vibratorythreshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy 〔J〕.DiabetesRes Clin Pract,1994,24：173～180.
